We conducted a case study of human immunodeficiency virus (HIV)-negative patients with cryptococcosis at 15 United States medical centers from 1990 through 1996 to understand the demographics, therapeutic approach, and factors associated with poor prognosis in this population. Of 306 patients with cryptococcosis, there were 109 with pulmonary involvement, 157 with central nervous system (CNS) involvement, and 40 with involvement at other sites. Seventy-nine percent had a significant underlying condition. Patients with pulmonary disease were usually treated initially with fluconazole (63%); patients with CNS disease generally received amphotericin B (92%). Fluconazole was administered to approximately two-thirds of patients with CNS disease for consolidation therapy. Therapy was successful for 74% of patients. Significant predictors of mortality in multivariate analysis included age у60 years, hematologic malignancy, and organ failure. Overall mortality was 30%, and mortality attributable to cryptococcosis was 12%. Cryptococcosis continues to be an important infection in HIV-negative patients and is associated with substantial overall and cause-specific mortality.
the majority of patients have significant underlying predisposing factors, particularly advanced HIV disease [4, 5] . Prior to the HIV disease epidemic, most patients with cryptococcosis had identifiable underlying disorders, such as glucocorticosteroid treatment, solid-organ transplantation, hematologic malignancy, sarcoidosis, or other disorders associated with cell-mediated immune dysfunction [6] [7] [8] . However, 10%-40% of HIVnegative patients with cryptococcosis have no apparent immune deficiency, although selective defects in lymphocyte responsiveness to C. neoformans or other subtle abnormalities may explain disease occurrence in otherwise normal hosts [9] [10] [11] [12] .
Until the mid-1970s, standard therapy for cryptococcal meningitis was administration of amphotericin B. The classic study of Bennett et al. [7] established the superior efficacy of combination therapy with amphotericin B and 5-flucytosine for cryptococcal meningitis in HIV-negative patients with this disorder. Fluconazole is a triazole with excellent in vitro and in vivo activity against C. neoformans and has been widely used for the treatment of cryptococcosis since it was approved by the US Food and Drug Administration in 1990 [13] . Large prospective studies subsequently established the importance of fluconazole in the management of cryptococcosis in HIV-infected patients [14, 15] . However, no published prospective study has addressed management of cryptococcosis in the HIV-negative patient in the era of effective azole therapy.
Current recommendations for treatment of cryptococcosis in this population are based on individual experiences, retrospective series, and extrapolations from the results of clinical trials with HIV-infected patients [16, 17] . Furthermore, all large published clinical trials have focused on meningitis, and to date there has been no large prospective study examining therapy for cryptococcosis at non-CNS sites.
Our study was designed to address several important issues related to cryptococcosis in HIV-negative patients: What are the current demographics and associated underlying conditions in this population? What factors are associated with a poor outcome? Do the triazole antifungal agents play an important role in the management of this disease? If so, does this role vary depending on site of involvement? What impact have therapeutic changes had on outcome? Our data represent the largest series of cases in HIV-negative patients with cryptococcosis reported to date and collectively demonstrate a broad spectrum of clinical disease with substantial morbidity and mortality.
METHODS
This case study included HIV-negative patients with cryptococcosis at 15 participating medical centers across the United States, during the period of July 1990 through December 1996. A case was defined as a patient with any one of the following: (1) a C. neoformans-positive culture specimen from any site; (2) positive histopathology; or (3) cryptococcal antigen-positive serum or CSF and a compatible clinical and/or radiographic presentation. All cases involved documentation of negative results of serological testing for HIV, or, in the absence of HIV testing, a clearly defined underlying disorder typically associated with cryptococcosis and the absence of any clinical or laboratory findings suggesting HIV positivity.
Cases were identified by review of mycology laboratory records, International Classification of Diseases, Ninth Revision (ICD-9) codes, and histopathologic and serological results. Standard case report forms were used for recording demographic, clinical, radiographic, culture, serological, diagnostic, and interventional data, in addition to information about specific antifungal therapy, immunosuppressive medications, and outcome. All case-report forms were reviewed by a data review committee (P.G.P., J.R.P., G.A.C., and M.S.H.) for accuracy and consistency of reporting before the final analysis and determination of final outcome, based on preset criteria.
Case definition. Cases were classified according to 2 criteria: (1) certainty of diagnosis and (2) site(s) of involvement. Cases were classified as proven, probable, possible, or colonization on the basis of the following criteria: "proven" extrapulmonary cases involved a C. neoformans-positive culture of a specimen from any extrapulmonary site or cryptococcal antigen-positive serum or CSF and positive results of histopathologic tests (special stains showing encapsulated budding yeasts). Pulmonary disease was considered to be proven on the basis of a positive respiratory tract culture and clinical or radiographic evidence of active pulmonary disease. "Probable" cases were defined by either a cryptococcal antigen test or positive results of histopathological testing, with a clinically and radiographically compatible presentation. "Possible" cases were defined by positive results of either positive results of cryptococcal antigen test or histopathological testing, but with an equivocal clinical or radiographic presentation. "Colonization" was identified on the basis of respiratory secretions that were culturepositive for C. neoformans but came from patients who were asymptomatic and had no radiographic evidence of cryptococcosis.
Sites of involvement were classified as follows: "pulmonary," for patients in whom the lungs and/or pleura were the only sites involved; "CNS," for patients with meningeal or parenchymal brain involvement, regardless of other sites involved; and "other," for patients with involvement at an extraneural, extrapulmonary site (e.g., skin, prostate, bone), with or without pulmonary involvement.
Therapy and outcome. Specific antifungal therapy was documented, including daily dose, cumulative dose (only for amphotericin B), and duration (days). Therapy was further classified as induction, consolidation, reinduction, and chronic suppressive therapy. "Induction therapy" was defined as initial therapy administered for at least 3 consecutive days for proven or suspected cryptococcosis. "Consolidation therapy" was defined as a regimen administered for active disease following a successful response to induction therapy. "Reinduction" was defined as intensified therapy following a poor response to either induction or consolidation therapy. "Chronic suppression" was defined as maintenance therapy given in the absence of disease activity to prevent relapsing disease.
Each investigator assessed final patient status, length of follow-up, date of relapse, and date and cause of death. Investigators specified whether cryptococcosis was an important contributing factor to death. Final outcome was classified by the data review committee as either success or failure, on the basis of the following criteria. "Success" was defined as cure (a complete response to therapy and no evidence of disease at least 6 months after completion of therapy) or improvement (a complete or partial response to therapy but with !6 months of follow-up after therapy). "Relapse" was defined as clinical, mycologic, or radiographic evidence of recrudescence after discontinuation of antifungal therapy, after initial improvement. "Failure" was defined as persistence or progression demonstrated through clinical, laboratory, radiographic, or mycologic evidence of disease despite antifungal therapy. "Death" was considered to be directly related to cryptococcosis on the basis of the opinion of the investigator; it was considered when death occurred within 7 days after diagnosis of cryptococcosis. Patients whose treatment data were inadequate or who did not receive antifungal therapy were considered unevaluable for efficacy.
Statistical analysis. All cases deemed eligible for study inclusion were categorized in the primary analysis by the site of involvement (pulmonary, CNS, or other). Categorical variables were analyzed by the x 2 test and continuous variables by the Kruskal-Wallis K-sample test [18] . Relationships between characteristics and 12-month survival were examined with Kaplan-Meier analysis, with the prognostic indicators compared by the log-rank test [19] . The Cox proportional hazards model was used to assess effects of potentially confounding variables on risk of any-cause mortality [20] .
RESULTS
A total of 319 patients were initially enrolled in the study, of whom 13 were excluded because they did not meet study criteria. Of the 306 patients who met study criteria, 251 (82%) had definite cryptococcosis, 40 (13%) had probable disease, 6 (2%) had possible disease, and 9 (3%) had pulmonary colonization with C. neoformans.
Baseline demographics, sites of involvement, and underlying conditions. As indicated in table 1, among 306 patients, 186 (61%) were male. Median age was 55 years (range, !1-84 years). Subjects with pulmonary disease were significantly older than other patients (61 years vs. 51 years;
). There P p .0028 were 109 patients (36%) with only pulmonary involvement, 157 (51%) with CNS disease, and 40 (13%) with involvement of other sites, including 10 with concomitant pulmonary disease. Most had significant predisposing factors. These included glucocorticosteroid therapy in 85 (28%), solid-organ transplantation in 54 (18%), chronic organ failure (renal or hepatic) syndromes in 55 (18%), rheumatologic disorders in 41 (13%), chronic lung disease in 38 (12%), hematologic malignancies in 29 (9%), other malignancies in 29 (9%), and other significant underlying conditions in 51 (17%), including splenectomy (9 patients). There was no significant predisposing condition in 66 patients (22%). Patients with pulmonary cryptococcosis were more likely to have chronic lung disease than other patients (27% vs. 5%;
), whereas patients with organ P ! .0001 failure syndromes were more likely to have cryptococcal infection involving CNS or other sites (6% vs. 24%;
). P ! .0001 Patients with CNS disease were also less likely to have underlying disease (30% vs. 13%;
). P p .001 Signs and symptoms. Clinical signs and symptoms attributable to cryptococcosis at the time of diagnosis varied according to site of involvement (table 2) . Constitutional signs or symptoms (fever, weight loss, night sweats) were most common among patients with CNS involvement (68%). Neurological signs and symptoms occurred in 145 (92%) patients with CNS involvement, particularly headache in 114 (73%) and altered mental status in 66 (42%). Other signs and symptoms were reported to occur in fewer than 30% of patients. Onefourth of patients with pulmonary involvement did not have documented respiratory symptoms.
Serological results. The baseline serum cryptococcal antigen assay was positive for 147 (74%) of 200 patients, including 91 (87%) of 105 patients with CNS disease, 40 (56%) of 71 patients with pulmonary disease, and 16 (67%) of 24 patients with disease at other sites. The median titer was 1:64 (range, 0 to 11:10 million). Initial CSF cryptococcal antigen tests were positive for 144 (97%) of 149 patients with CNS involvement, with a median titer of 1:256 (range, 0 to 11:10 million). Followup CSF cryptococcal antigen titers determined at least 7 days after the initial positive finding but within 40 days of the original diagnosis were positive in 70 (88%) of 80 patients, with a median value of 1:64 (range, 0 to 1:8192), a 4-fold decrease from the median initial CSF titer.
CSF findings.
Among patients with CNS involvement, lumbar punctures were performed at baseline in 154 (98%) of 157 patients. Three patients did not undergo baseline lumbar punctures; 2 patients were diagnosed with CNS cryptococcosis post-mortem, and in 1 patient, lumbar puncture was performed 2 months after initiation of antifungal therapy. Culture of CSF for C. neoformans was positive for 132 (89%) of 149 patients, and India ink preparations were positive for 68 (51%) of 133 patients. At least 1 of the 3 tests (culture, India ink preparation, cryptococcal antigen) was positive for 152 (97%) of 157 patients. (15) 47 (30) 4 (10) 66 (22) Hematologic malignancy 8 (7) 17 (11) 4 (10) 29 (9) Other malignancy 15 (14) 8 (5) 6 (15) 29 (9) Chronic hepatic failure 4 (4) 25 (16) 9 (23) 38 (12) Chronic renal failure 3 (3) 7 (4) 7 (18) 17 (6) Chronic lung disease 29 (27) 6 (4) 2 (5) 38 (12) Rheumatologic disease 15 (14) 20 (13) 6 (15) 41 (13) Solid-organ transplant 20 (18) 23 (15) 11 (28) pharmacologic therapy, ventricular shunting), including 17 (11%) in whom a permanent ventricular shunt was placed.
Antifungal therapy and outcome. Outcome was assessed according to site of involvement and induction regimen (table  3) . Details concerning induction and consolidation therapy and outcome are described below for each disease category.
Pulmonary disease. Ninety-two (84%) of 109 patients with pulmonary disease received antifungal therapy. Among these cases, 74 (68%) had a successful outcome (cure or improvement); 11 (10%) were treatment failures, and 24 (22%) were unevaluable. Of the 92 patients who received antifungal therapy, 58 were given induction therapy with fluconazole alone, at a median dose and duration of 400 mg and 92 days (1-566 days). An additional 19 patients received induction therapy with amphotericin B alone, and 9 received amphotericin B plus 5-flucytosine. The median total dose and duration of amphotericin B were 460 mg (60-2530 mg) and 13 days (2-96 days). Six patients were treated with other regimens.
Consolidation fluconazole therapy was given to 21 patients, 19 of whom had received induction therapy with amphotericin B initially. The median dose and duration of fluconazole for consolidation therapy were 400 mg and 201 days (10-828 days). Nineteen (90%) of 21 patients were successfully treated, 1 experienced treatment failure, and 1 was unevaluable. Seven patients with pulmonary disease required reinduction therapy with amphotericin B after displaying an inadequate response to induction therapy with fluconazole. Five of these patients responded to reinduction therapy. Three patients received chronic suppressive therapy for maintenance, using fluconazole at a daily dose of 200 mg, for a mean duration of 491 days.
CNS disease. Among patients with CNS cryptococcosis, 154 (98%) of 157 received antifungal therapy. Overall, 127 patients (81%) with CNS cryptococcosis were successfully treated, 26 (16%) experienced treatment failures, and 4 (3%) were unevaluable. Induction therapy involved administration of amphotericin B plus 5-flucytosine to 107 patients (68%), amphotericin B alone to 27 (17%), and amphotericin B plus fluconazole to 7 (5%). The median cumulative dose and duration of amphotericin B were 805 mg and 27 days. The median daily dose and duration of therapy with 5-flucytosine were 6000 mg and 31 days. Eight patients received fluconazole alone at a median dose of 300 mg for a median duration of 89 days. Five patients received induction therapy with fluconazole and 5-flucytosine. Consolidation therapy with fluconazole was given to 99 patients at a median dose and duration of 400 mg and 70 days. Five patients received concomitant flucytosine in addition to fluconazole. Ninety-three (94%) of 99 patients were successfully treated. Reinduction therapy was needed by 16 patients whose clinical response to fluconazole consolidation therapy was poor, and 15 of these patients received amphotericin B alone or in combination with 5-flucytosine and/or fluconazole for reinduction therapy. The median dosage of amphotericin B for reinduction was 650 mg for a duration of 29 days. Sixteen patients were given fluconazole as chronic suppressive therapy at a median dose and duration of 400 mg and 681 days (391-1833 days).
Disease at other sites. Of 40 patients with cryptococcosis at sites other than CNS or lungs, 36 (90%) received antifungal therapy. Twenty-five (63%) of 40 patients were successfully treated, 8 (20%) were treatment failures, and 7 (18%) were not evaluable. Twenty-three patients (58%) received amphotericin B, including 8 patients who received either concomitant 5-flucytosine (6 patients) or fluconazole (2 patients). The median dose and duration of amphotericin B were 450 mg and 17 days. Twelve patients (30%) received fluconazole alone at a median daily dose and duration of 200 mg and 37 days. One patient received other therapy. Thirteen patients received consolidation therapy with fluconazole, including 2 who received concomitant flucytosine, at a median dose and duration of 200 mg and 201 days. Ten (77%) of the 13 patients were successfully treated, 2 (15%) were treatment failures, and 1 (8%) was unevaluable.
Relapses. Relapse after cessation of therapy occurred in 12 (4%) of 306 patients. Most relapses were established by clinical, radiographic, and serological evidence (10 patients) rather than a positive culture for C. neoformans (2 patients). There were 6 relapses in the CNS group, 5 relapses in the pulmonary group, and 1 relapse in the group of patients with disease at other sites. With regard to induction therapy, relapse occurred in 5 (7%) of 70 patients who received amphotericin B without 5-flucytosine, 2 (2%) of 122 patients who received amphotericin B plus 5-flucytosine, 4 (5%) of 78 patients who received fluconazole, and 1 (8%) of 12 patients who received treatment with other agents. Only 1 patient, a liver transplant recipient with chronic rejection, died of relapsing cryptococcosis.
Survival. Any-cause mortality for 12 months was assessed according to site of involvement and underlying disease ( figures  1 and 2) . Mortality related to all causes was 30% (91 patients), and the rate of cause-specific mortality (death due to cryptococcosis) was 12% (36 patients). The cause-specific mortality among patients with other-site involvement was 24%; with CNS involvement, 16%; and with pulmonary involvement, 5%. Causespecific mortality for patients with organ failure syndromes was 34%; with hematologic malignancy, 21%; with no underlying disorder, 12%; with chronic glucocorticosteroid therapy, 13%; with a transplant, 9%; and with other conditions, 8%.
Factors influencing mortality. We assessed factors with a potential impact on mortality by means of univariate and multivariate analyses. In the univariate model for all patients, the factors significantly associated with mortality were organ failure or hematologic malignancy as an underlying disease (P p ); unsuccessful therapy ( ); site of infection other .0001 P p .0001 than pulmonary ( ); age у60 years ( ); and a P p .001 P p .001 positive blood culture for C. neoformans ( ). Induction P p .02 therapy with amphotericin B and gender did not affect mortality in the overall population (table 4) .
Among patients with CNS involvement, factors significantly associated with mortality by univariate analysis were underlying hematologic malignancy or an organ failure syndrome (P p ), male gender ( ), absence of headache ( .0001 P p .05 P p ), and altered mental status at presentation ( ), .001 P p .02 whereas constitutional symptoms, induction therapy with amphotericin B, papilledema, positive results of India ink preparations, changes in CSF cryptococcal antigen findings, and opening pressure were not significantly associated with mortality. Absence of meningismus was marginally associated with mortality (
). Among patients with pulmonary involve-P p .06 ment, factors significantly associated with mortality were underlying organ failure ( ), age у60 years ( ), P p .002 P p .001 and male gender ( ). Among patients with disease at P p .05 other sites, organ failure syndromes ( ) and male gen-P p .002 der ( ) were significantly associated with mortality. In P p .04 the latter 2 groups, positive blood cultures and induction with amphotericin B did not influence mortality.
By multivariate analysis, as shown in table 5, factors significantly correlated with decreased survival in the overall population were organ failure ( ), hematologic malig-P p .0001 nancy ( ), and age у60 years ( ); site of P p .04 P p .0001 infection did not significantly influence mortality. Among patients with CNS disease, factors significantly associated with mortality were male gender ( ), absence of headache P p .02 ( ), altered mental status ( ), organ failure P p .005 P p .04 ( ), and hematologic malignancy ( ), whereas P p .006 P p .0002 constitutional symptoms, meningismus, and amphotericin B induction therapy did not significantly influence mortality. Among patients with pulmonary disease, factors significantly associated with mortality were age у60 years ( ) and P p .0001 organ failure ( ). P p .005
DISCUSSION
The present study demonstrates that despite the availability of newer antifungal agents such as fluconazole, cryptococcal disease in HIV-negative hosts continues to be associated with substantial morbidity and mortality. We observed that there is significant variability with respect to therapeutic management, depending on anatomic site and severity of disease. With both univariate and multivariate analyses, we have identified several factors associated with mortality in the overall population and among specific groups of patients with CNS, pulmonary, or other sites of cryptococcosis. Age у60 years and the presence of significant underlying disease, especially organ failure syndromes and hematologic malignancy, are consistently associated with mortality in all groups.
Therapy for cryptococcosis has evolved since the development of fluconazole and other triazoles. Most recent therapeutic data have been generated from clinical trials conducted among HIV-infected patients with cryptococcosis [14, 15, [21] [22] [23] . The last prospective randomized trial for the treatment of cryptococcal meningitis in predominantly HIV-negative patients was published more than a decade ago [8] . Subsequent randomized trials conducted among HIV-positive subjects have established an important role for fluconazole and, to a lesser extent, itraconazole in the management of this disorder [14, 15, 21, 22] .
In their report on a retrospective study of 83 HIV-negative patients with cryptococcosis, Dromer et al. [24] suggested that outcomes were not influenced by site of involvement, severity of illness, or whether amphotericin B or fluconazole was given as initial therapy. Predictors of death among their patients included age 160 years, underlying neoplastic disease, abnormal mental status, extrapulmonary disease, and treatment failure [24] .
On the basis of data from randomized clinical trials, traditional therapy for HIV-negative patients with cryptococcal meningitis has been at least 6 weeks of therapy with a combination of amphotericin B and flucytosine [7, 8, 16] . As little as 4 weeks is an effective duration for carefully selected HIVnegative patients who are not severely immunocompromised [8] . However, the studies yielding these findings were completed before the availability of fluconazole. In the present study, 90% of patients with CNS disease received amphotericin B with or without 5-flucytosine as induction therapy for a median of 4 weeks.
Approximately two-thirds of our patients with CNS disease who were successfully treated with an induction regimen that included amphotericin B subsequently received fluconazole. In most instances, the switch to fluconazole was made after substantial clinical improvement. Most of our patients received fluconazole for a limited period (median, 10 weeks), after which the drug was withdrawn. Only 16 (13%) of 127 of our successfully treated patients, most of whom had significant ongoing immunosuppression, received chronic suppressive therapy with fluconazole. The overall success rate (81%) among our patients with CNS disease compares favorably with that in published trials among HIV-negative patients [7, 8] . However, the relapse rate in the present study was considerably less (4%) than in previous reports. We believe that an important factor leading to fewer relapses among these patients was the extensive use of fluconazole for consolidation therapy, often given for months after clinical and mycologic improvement. Patients with cryptococcosis limited to the lungs were treated in a manner quite different than those with CNS disease. A substantial number (17 of 109 patients) did not receive specific antifungal therapy and thus were unevaluable for therapeutic efficacy. Among those patients who received specific antifungal therapy, 58 (63%) received fluconazole for ∼3 months. Of the remaining 34 patients, most received amphotericin B as induction therapy for р2 weeks, and, following clinical improvement, three-quarters received fluconazole for ∼6 months. The overall success of therapy for these patients with pulmonary disease was 68%, but when unevaluable patients who did not receive antifungal therapy are excluded, 84% patients were successfully treated. These figures are consistent with the published efficacy of antifungal therapy with fluconazole for pulmonary cryptococcosis in 3 small retrospective studies [24] [25] [26] .
Several studies have suggested the use of observation alone for asymptomatic or minimally symptomatic patients without significant underlying immunosuppression [27] [28] [29] , and on the basis of our data, this appears to be a relatively common clinical practice (17 of 109 patients). In the absence of prospective trials for treatment of pulmonary cryptococcosis, there is no "gold standard" for antifungal therapy, and treatment decisions should be guided by severity of illness and underlying disease. The present study suggests that fluconazole is adequate therapy for most patients with infection limited to the lungs.
Patients with cryptococcosis involving extraneural and extrapulmonary sites had the worst prognosis and the highest percentage of failed therapy (20%). This group of patients is the least studied among all patients with cryptococcosis, and our data suggest that the substantially higher overall mortality in this group reflects not only significant underlying disease but also delays in diagnosis and institution of therapy, possibly due to an atypical clinical presentation (e.g., cellulitis). Most of these patients were initially treated with regimens that included amphotericin B, and only approximately one-half were successfully treated. In contrast, all of the patients treated with fluconazole alone had successful outcomes, which may reflect a bias towards administering fluconazole to patients with less severe disease.
We observed several important factors that affected survival. Age у60 years, underlying hematologic malignancy, and organ failure syndromes were strongly associated with increased mortality among the overall study population, consistent with previous reports [6] [7] [8] 24] . It is surprising that the outcomes for organ transplant recipients were good overall and not significantly different from those for patients without underlying disease, an observation that may reflect the attention directed toward these patients and the intensity with which they are evaluated and treated [30, 31] . Among patients with CNS disease, altered mental status and absence of headache were significantly associated with mortality, findings which are consistent with previous reports [6] [7] [8] . Although previous reports suggested additional poor prognostic factors, including in- creased opening pressure, positive results of India ink preparations, and higher cryptococcal antigen titers [6] [7] [8] , these were not predictors of mortality in the present study. There appeared to be no significant difference in outcome with regard to induction antifungal regimen (amphotericin B vs. other). Delays in diagnosis probably increase the overall morbidity and mortality among patients with cryptococcosis. We observed constitutional symptoms such as weight loss, night sweats, and fever in !60% of our patients overall. Patients with CNS disease usually had headache, altered mental status, and other neurological symptoms, but these were typically subacute, often developing over several weeks or months. For patients with pulmonary cryptococcosis, cough was the only symptom present in the majority of patients, and one-quarter had no respiratory symptoms.
Furthermore, serum cryptococcal antigen testing for screening is far less reliable for non-HIV-infected patients than for HIV-positive patients with cryptococcosis. Among our patients, such testing was positive for only 56% and 86% of those with pulmonary and CNS disease, respectively, whereas, among HIVpositive patients, almost all with cryptococcosis have positive serum cryptococcal antigen titers [32] . Taken together, these observations suggest that many HIV-negative patients with cryptococcosis present with few or minimal signs and symptoms; for these patients, serological testing is insensitive, a circumstance that may lead to costly delays in diagnosis and institution of therapy.
In summary, cryptococcosis continues to be an important infection in HIV-negative patients, particularly in those with significant underlying immunosuppression. Our data provide several important insights valuable to the overall understanding of the condition of HIV-negative patients with cryptococcosis.
Fluconazole has emerged as an important therapeutic agent in this population, but its specific role with regard to dosing, duration of therapy, and timing of intervention varies with site of involvement, disease severity, and underlying disease. Clearly, the major role for fluconazole among patients with CNS disease is in consolidation therapy after successful induction with amphotericin B and 5-flucytosine. The appropriate dose and duration of amphotericin B remain unclear, but dosages of 0.6-0.8 mg/kg daily, together with 5-flucytosine (100 mg/kg daily) for at least 2-4 weeks seem reasonable in most instances [33] .
For patients with pulmonary cryptococcosis, administration of fluconazole is often effective as primary treatment for uncomplicated disease. Long-term chronic suppression with fluconazole for HIV-negative patients with cryptococcosis appears to have a minor role and probably should be limited to patients with disorders associated with significant ongoing immunosuppression and evidence of persistent disease. 
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